Concepedia

Vicki Goodman

VG

20

Publications

6K

Citations

20

H-Index

2007

Active since

Affiliations

GlaxoSmithKline (United States)(Current)

Memorial Sloan Kettering Cancer Center

University Hospital Schleswig-Holstein

University of Lübeck

Sir Charles Gairdner Hospital

Vicki Goodman is an author at GlaxoSmithKline (United States) specializing in medicine, cancer therapeutics, and oncology.

Top concepts

Publications per year

2007–2020

20

Publications

20

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Axel Hauschild, Jean‐Jacques Grob, Lev Demidov et al. · The Lancet · 2012 · 2.9K citations

, , +6

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

Georgina V. Long, Uwe Trefzer, Michael A. Davies et al. · The Lancet Oncology · 2012 · 901 citations

, , +6

Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma

Paolo A. Ascierto, David R. Minor, Antoni Ribas et al. · Journal of Clinical Oncology · 2013 · 422 citations

Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma

Edwin P. Rock, Vicki Goodman, Janet Jiang et al. · The Oncologist · 2007 · 242 citations · Full text

, , +13

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

Michael H. Brave, Vicki Goodman, Edvardas Kaminskas et al. · Clinical Cancer Research · 2008 · 239 citations

Rows per page

1–5 of 20